Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

285 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Peripheral-blood stem cells versus bone marrow from unrelated donors.
Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, Cutler CS, Westervelt P, Woolfrey A, Couban S, Ehninger G, Johnston L, Maziarz RT, Pulsipher MA, Porter DL, Mineishi S, McCarty JM, Khan SP, Anderlini P, Bensinger WI, Leitman SF, Rowley SD, Bredeson C, Carter SL, Horowitz MM, Confer DL; Blood and Marrow Transplant Clinical Trials Network. Anasetti C, et al. Among authors: maziarz rt. N Engl J Med. 2012 Oct 18;367(16):1487-96. doi: 10.1056/NEJMoa1203517. N Engl J Med. 2012. PMID: 23075175 Free PMC article. Clinical Trial.
Sociodemographic Factors Influencing Access to Chimeric Antigen T-Cell Receptor Therapy for Patients With Non-Hodgkin Lymphoma.
Khare S, Williamson S, O'Barr B, Schachter L, Chen A, Hayes-Lattin B, Leonard J, Desai A, Ferreira-Gandolfo P, Christmas K, Lackey D, Maziarz RT, Nemecek ER. Khare S, et al. Among authors: maziarz rt. Clin Lymphoma Myeloma Leuk. 2024 Sep 27:S2152-2650(24)02355-3. doi: 10.1016/j.clml.2024.09.010. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 39426942
Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy.
Wudhikarn K, Tomas AA, Flynn JR, Devlin SM, Brower J, Bachanova V, Nastoupil LJ, McGuirk JP, Maziarz RT, Oluwole OO, Schuster SJ, Porter DL, Bishop MR, Riedell PA, Perales MA. Wudhikarn K, et al. Among authors: maziarz rt. Blood Adv. 2023 Jul 11;7(13):3192-3198. doi: 10.1182/bloodadvances.2022008294. Blood Adv. 2023. PMID: 36355838 Free PMC article.
Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome.
Bhaskar ST, Patel VG, Porter DL, Schuster SJ, Nastoupil LJ, Perales MA, Tomas AA, Bishop MR, McGuirk JP, Maziarz RT, Chen AI, Bachanova V, Maakaron JE, Riedell PA, Oluwole OO. Bhaskar ST, et al. Among authors: maziarz rt. Blood Adv. 2023 Sep 12;7(17):4765-4772. doi: 10.1182/bloodadvances.2022008937. Blood Adv. 2023. PMID: 36508286 Free PMC article.
Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel Recipients for B Cell Non-Hodgkin Lymphoma.
Ahmed N, Wesson W, Mushtaq MU, Porter DL, Nasta SD, Brower J, Bachanova V, Hu M, Nastoupil LJ, Oluwole OO, Patel VG, Oliai C, Riedell PA, Bishop MR, Shah GL, Perales MA, Schachter L, Maziarz RT, McGuirk JP. Ahmed N, et al. Among authors: maziarz rt. Transplant Cell Ther. 2023 Jul;29(7):449.e1-449.e7. doi: 10.1016/j.jtct.2023.04.019. Epub 2023 Apr 27. Transplant Cell Ther. 2023. PMID: 37120134 Free PMC article. Review.
CAR T-Cell Immunotherapy in Minority Patients with Lymphoma.
Ghilardi G, Williamson S, Pajarillo R, Paruzzo L, Chen L, Grady C, Doucette A, Nemecek E, Gabrielli G, Barta SK, Svoboda J, Chong EA, Yelton R, Nasta SD, Landsburg DJ, Ugwuanyi O, Chen AI, Schachter L, White G, Ballard HJ, Weber E, Curley C, Porter DL, Garfall AL, Hwang WT, Guerra CE, Maziarz RT, Schuster SJ, Ruella M. Ghilardi G, et al. Among authors: maziarz rt. NEJM Evid. 2024 Apr;3(4):EVIDoa2300213. doi: 10.1056/EVIDoa2300213. Epub 2024 Mar 26. NEJM Evid. 2024. PMID: 38776868
Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma.
Scordo M, Flynn JR, Gonen M, Devlin SM, Parascondola A, Tomas AA, Shouval R, Brower J, Porter DL, Schuster SJ, Bachanova V, Maakaron J, Maziarz RT, Chen AI, Nastoupil LJ, McGuirk JP, Oluwole OO, Ip A, Leslie LA, Bishop MR, Riedell PA, Perales MA. Scordo M, et al. Among authors: maziarz rt. Blood Adv. 2023 Sep 26;7(18):5579-5585. doi: 10.1182/bloodadvances.2023010302. Blood Adv. 2023. PMID: 37522731 Free PMC article.
Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy.
Gazeau N, Liang EC, Wu QV, Voutsinas JM, Barba P, Iacoboni G, Kwon M, Ortega JLR, López-Corral L, Hernani R, Ortiz-Maldonado V, Martínez-Cibrian N, Martinez AP, Maziarz RT, Williamson S, Nemecek ER, Shadman M, Cowan AJ, Green DJ, Kimble E, Hirayama AV, Maloney DG, Turtle CJ, Gauthier J. Gazeau N, et al. Among authors: maziarz rt. Transplant Cell Ther. 2023 Jul;29(7):430-437. doi: 10.1016/j.jtct.2023.04.001. Epub 2023 Apr 7. Transplant Cell Ther. 2023. PMID: 37031746 Free PMC article.
Day 4 collection of granulocyte colony-stimulating factor-mobilized HLA-matched sibling donor peripheral blood allografts demonstrates no long-term increase in chronic graft-versus-host disease or relapse rates.
Booth G, Yu Y, Harlan RP, Jacoby CE, Tomic KM, Slater SE, Allen BE, Berklich EM, Knight RJ, Dela Cruz J, Fu R, Gandhi A, Cook RJ, Meyers G, Maziarz RT, Newell LF. Booth G, et al. Among authors: maziarz rt. Cytotherapy. 2023 Apr;25(4):423-431. doi: 10.1016/j.jcyt.2022.11.004. Epub 2023 Jan 21. Cytotherapy. 2023. PMID: 36690537
285 results